Regeneron's Trading Volume Surges 34.95% to $552 Million Ranking 180th in Market Activity

On July 15, 2025, Regeneron's trading volume reached $552 million, marking a 34.95% increase from the previous day, ranking 180th in the day's stock market activity. Regeneron's stock price fell by 3.97%.

Regeneron Pharmaceuticals, Inc. announced that its board of directors has declared a quarterly dividend of $0.60 per share on the company's common stock. The dividend is payable on September 15, 2025, to stockholders of record at the close of business on August 15, 2025.

Regeneron Pharmaceuticals, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its new drug, Eylea, for the treatment of wet age-related macular degeneration. This approval is expected to significantly boost the company's revenue and market share in the ophthalmology sector.

Regeneron Pharmaceuticals, Inc. has announced that it will be hosting its annual shareholders meeting on August 10, 2025. The meeting will be held virtually, and shareholders are encouraged to participate and vote on important company matters.